Project Grant HT94252410671
Award Date
9/15/24
Completion Date
9/14/27
Dollars Obligated
$326K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10016, USA
Similar Awards
The U.S. Department of Defense's Military Medical Research and Development program (CFDA 12.420) has awarded a $1,309,471 Project Grant to New York University (NYU) School of Medicine to conduct research on the "Genomic and Molecular Imprints of Carcinogenic Benzene Exposure." The project, which spans from September 2024 to September 2027, will investigate the molecular mechanisms and genetic markers associated with benzene exposure and its relationship to cancer development. As a...
This federal Project Grant award from the Department of Defense's Military Medical Research and Development program (CFDA 12.420) provides $975,210.00 to New York University (NYU) School of Medicine to conduct research on the "Genomic and Molecular Imprints of Carcinogenic Benzene Exposure". The award period runs from September 15, 2024 to September 14, 2027. Through this funding, NYU School of Medicine will carry out innovative biomedical research investigating the genetic and...
The Department of Defense's Military Medical Research and Development program (CFDA 12.420) awarded a $680,757 project grant to New York University School of Medicine to conduct research titled "Targeting RAGE After Particulate Matter Exposure: Metabolic Dysregulation and Disease Mitigation." The grant, effective July 1, 2025 through June 30, 2028, will support advanced biomedical research aimed at transforming healthcare for military service members, veterans, and the broader...
New York University School of Medicine was awarded a $762,750 Project Grant from the Defense Health Agency under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund a research project titled "BEYOND VEXAS AND UBA1: IDENTIFICATION OF NOVEL DRIVERS OF MDS AUTOIMMUNE SYNDROMES" from June 15, 2023 through June 14, 2026. The grant supports research to identify novel drivers of myelodysplastic syndromes, blood disorders that can progress...
The U.S. Department of Defense's Military Medical Research and Development (CFDA 12.420) program awarded a $749,343 project grant to New York University (NYU) on August 1, 2025. The grant supports a 2-year research project titled "P15-1 PEPTIDE TREATMENT FOR CARTILAGE INJURIES AND POST-TRAUMATIC OSTEOARTHRITIS" to be completed by July 31, 2027. Through this funding, NYU will conduct advanced biomedical research to develop innovative treatments for cartilage injuries and...
New York University School of Medicine was awarded a $911,777 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development federal grant program (CFDA 12.420). The grant will fund research into Mitochondrial Dynamics as a Therapy Target in Myelodysplastic Syndromes. Through September 2025, NYU School of Medicine researchers will investigate medical solutions for blood cancers like MDS by exploring mitochondrial functions and their potential as...
This federal Project Grant award, valued at $254,153.00, was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports advanced biomedical research at New York University (NYU) School of Medicine to investigate the relationship between microplastics and prostate cancer. The project will be conducted over a 2-year period from March 1, 2025 to February 28, 2027. As a leading academic medical center and research...
The Department of the Army Medical Command awarded New York University School of Medicine a $1,186,500 project grant under the Military Medical Research and Development program (CFDA 12.420). The grant will fund research from September 2021 through August 2024 to understand the transition from nevi to melanoma occurring within the skin epidermis. The Military Medical Research and Development program supports basic, applied, and advanced biomedical research with the goals of transforming military...
The Defense Health Agency awarded a $1,694,245 Project Grant to New York University (NYU) School of Medicine, a private non-profit research institution and medical school, to develop innovative therapeutics against pressure ulcer-associated bacteria. The 4-year grant, which runs from August 2023 to August 2027, is funded under the Military Medical Research and Development program (CFDA 12.420). Through this award, NYU School of Medicine will conduct research to identify and advance new...
The Defense Health Agency has awarded a $1,674,999.00 Project Grant to Yale University under the Military Medical Research and Development program (CFDA 12.420). The grant is for the "PERTURBOMICS IDENTIFICATION OF CRITICAL GENETIC TARGETS IN NK CELLS FOR BREAST CANCER THERAPY" project, which will be conducted from September 1, 2023 to August 31, 2026. The funding will support basic, applied, and advanced biomedical research to transform healthcare for service members and the public...